BioHarvest Sciences Inc. (BHST) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong revenue growth, improved gross margins, and a strategic focus on expanding VINIA products and CDMO services. The Q&A section reveals positive sentiment towards new product launches and partnerships, despite some uncertainty in management's timeline clarity. The company's strategic initiatives and financial metrics indicate a positive outlook, leading to a positive sentiment rating.
Key Financial Performance
Total Revenue $9.1 million in Q3 2025, a 39% increase year-over-year from $6.5 million in Q3 2024. This growth was driven by sustained momentum in core VINIA capsules, the expanding success of the VINIA Inside product portfolio, and significant contributions from the CDMO customer base.
Product Revenue $8.4 million in Q3 2025, a 30% increase year-over-year. Growth was fueled by strong performance in core capsules (88% of product revenue) and new products (12% of product revenue), including double-digit growth in tea and coffee businesses and the launch of VINIA 2X Formula Chews.
CDMO Revenue $0.7 million in Q3 2025, a 722% increase year-over-year. Growth was attributed to milestone-based project revenues and new deals, including a partnership with Saffron Tech.
Gross Profit $5.6 million in Q3 2025, a 50% increase year-over-year from $3.7 million in Q3 2024. Gross margin improved to 61% from 57%, driven by increased manufacturing scale and improved yields.
Operating Expenses $6.5 million in Q3 2025, up from $5.8 million in Q3 2024. The increase was due to higher marketing spend, development of the Health Pros affiliate program, and expenses for the CDMO service division, partially offset by lower general and administrative expenses.
Net Loss $2.5 million in Q3 2025, an improvement from a net loss of $2.7 million in Q3 2024. The improvement was due to higher revenue and gross profit, partially offset by increased operating expenses.
Adjusted EBITDA Loss $0.4 million in Q3 2025, an improvement from $1.7 million in Q3 2024. The improvement reflects higher revenue and gross profit, along with disciplined expense management.
Cash and Cash Equivalents $11 million as of September 30, 2025, up from $2.4 million as of December 31, 2024. The increase was due to a $19.9 million institutional equity raise in November 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
VINIA 2X Formula Chews: Successfully launched with a record review rating of 4.8 out of 5 on Amazon.
VINIA BloodFlow Hydration Solution: Launched VIP early adopter rollout on November 10, with a broader public launch planned for December 3. Targets the $17 billion U.S. electrolyte hydration market with unique benefits like improved blood flow and hydration.
CDMO partnership with Saffron Tech: Secured a partnership to develop saffron-derived compounds, with BioHarvest retaining 25% ownership of the resulting compound. This addresses supply constraints in the saffron market.
VINIA Health Pros professional affiliate program: Launched Phase 1, onboarding 75 health professionals, with a target of 300 by year-end. Aims to expand reach and credibility in the health and wellness community.
Revenue Growth: Achieved a 39% year-over-year increase in total revenues to $9.1 million in Q3 2025.
Gross Profit Margins: Increased to 61%, benefiting from manufacturing scale and improved yields.
Adjusted EBITDA: Loss reduced to $0.4 million in Q3 2025, compared to $1.7 million in the same quarter of the previous year.
Capital Markets: Raised $30.8 million through equity financing and debt reduction, fully funding the next growth phase and enabling manufacturing capacity expansion.
Strategic Investments: Plans to invest in bioreactor capacity, process automation, and quality systems to support growth in both VINIA and CDMO businesses.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Conditions: The company faces challenges in achieving adjusted EBITDA breakeven, with projections indicating this milestone may not be reached until early 2026. This delay could impact investor confidence and financial stability.
Competitive Pressures: The launch of the VINIA BloodFlow Hydration Solution into the $17 billion U.S. electrolyte hydration market introduces competition with established players, requiring significant differentiation and marketing efforts to capture market share.
Regulatory Hurdles: No explicit regulatory challenges were mentioned, but the company's expansion into new product categories and markets may involve compliance risks.
Supply Chain Disruptions: The company is heavily reliant on its Botanical Synthesis technology for production. Any disruptions in this proprietary process could significantly impact operations and revenue.
Economic Uncertainties: The company has fortified its balance sheet with recent equity financing, but economic uncertainties could affect consumer spending on nutraceuticals and health products, impacting revenue growth.
Strategic Execution Risks: The success of the Health Pros affiliate program and the VINIA BloodFlow Hydration rollout are critical to future growth. Failure to scale these initiatives effectively could hinder revenue and market expansion.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: The company expects fourth quarter revenue in the range of $9 million to $9.5 million.
Adjusted EBITDA Projections: The company anticipates adjusted EBITDA between negative $0.6 million and 0 for Q4 2025, with breakeven expected by early 2026.
VINIA BloodFlow Hydration Launch: The company is preparing for an aggressive rollout of the VINIA BloodFlow Hydration product, targeting the $17 billion U.S. electrolyte hydration market. A broader market-wide public launch is scheduled for December 3, 2025.
Health Pros Affiliate Program Expansion: The company plans to expand the Health Pros affiliate program to approximately 300 professionals by year-end 2025, following the success of Phase 1.
CDMO Business Growth: The company expects additional CDMO partners to onboard in the coming quarter, building on the success of the Saffron Tech partnership.
Capital Expenditures and Manufacturing Capacity: The company plans to triple its manufacturing capacity and invest in additional bioreactor capacity, process automation, quality systems, and tooling to support growth in both VINIA and CDMO businesses.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the expected ramp-up for the new hydration product?
A:The hydration product is part of a $17 billion U.S. electrolyte hydration category. The company launched VINIA BloodFlow Hydration to existing customers through engaging emails, with shipments starting mid-next week. A broader launch with marketing assets (TV, YouTube, Instagram, Health Pros) will begin on December 3. Amazon sales are expected to start in early January due to distribution delays. The company is also targeting gyms and other points of sweat through its Health Pros affiliate network. A quarter-on-quarter ramp-up is expected, with heavy marketing focus on BloodFlow Hydration.
Q:What is the next step after running Stage 1 and Stage 2 in parallel for the Saffron Tech agreement?
A:The company will optimize Saffron Tech's existing cell bank and transfer it into liquid media, progressing to small and medium bioreactors. If successful, they will move to large-scale bioreactors. Simultaneously, they will leverage their IP to start Stage 1 tissue culture work. The goal is to create a 'super saffron' product, similar to their success with Resveratrol, and bring it to market through BioHarvest's e-commerce and B2B channels.
Q:What is the status of other pre-existing CDMO contracts nearing Stage 2?
A:In the cosmetic fragrance space, progress is being made with tissue culture work in local laboratories. For Tate & Lyle, one plant has been accessed, and a second plant is being sourced to increase chances of success. The pharmaceutical company has moved to Stage 2.
Q:Has there been increased interest from potential partners after the exosome creation announcement?
A:Yes, the pipeline is rich with significant deal flow from pharmaceutical, nutraceutical, and cosmetic customers. The exosome technology has strengthened the value proposition for CDMO customers, particularly in cosmetics and nutraceuticals. The company plans to announce another deal before year-end and is working on downstream process development for exosome extraction as part of their new manufacturing facility.
Q:What are the early successes of the Health Pros program?
A:The company has built an end-to-end affiliate system for seamless onboarding of Health Pros. Initial onboarding of 75 Health Pros provided learnings, and the goal is to onboard 300 by year-end. Health Pros with significant social media ecosystems have shown high conversion rates and lower customer acquisition costs. The hydration product is expected to further accelerate the program.
Q:What is the long-term outlook for the CDMO business as a percentage of total revenue?
A:In 5-7 years, the CDMO business is expected to contribute 75% of total revenue, with the remaining 25% from the products business. The CDMO business has higher margins (70-80%) compared to the products business (60-65%). The company is targeting strategic profit pools with high utility value for their technology.
Q:What feedback has been received from the VIP early adopter launch of VINIA BloodFlow Hydration?
A:The initial response has been positive, with significant sales of the first 1,000 variety packs. The product's taste has been well-received, and the company is optimistic about its differentiation and disruption in the market. Conversion rates on the landing page are strong, and repeat purchase rates will be monitored.
Q:What is the timeline for reaching Phase 2 of the Health Pro affiliate program?
A:The company aims to onboard 300 Health Pros by December 31, 2023, and then scale to 500, 700, and eventually 1,000. The focus is on providing Health Pros with a scalable revenue model and a seamless onboarding experience.
Q:How is the company planning to use its funds and manage resources?
A:The company plans to use funds to build a second manufacturing facility in a modular way, operational by Q2 2027. They aim to grow revenue, improve gross margins, and achieve adjusted EBITDA breakeven in the near term. Resource management will remain disciplined to ensure purposeful use of funds.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the timeline for achieving profitability in the CDMO business and the exact revenue contribution from new deals. Additionally, responses about the exosome technology's downstream process development and its market readiness lacked clarity and specific timelines.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Amazon moment
BB partnership
Bar financials
BioHarvest addition
BioHarvest ownership
BioHarvest stage
BloodFlow Hydration
Botanical Synthesis
CDMO company
CDMO customer
CDMO increase
CDMO role
CDMO saffron
Core capsule
GA capital
Health Pros
Hydration solution
Hydration stream
Phase onboarding
Pros affiliate
Stage
VINIA BloodFlow
VIP
affiliate program
balance sheet
base
debt
driver
electrolyte
financing
nutraceuticals
proceeds
rollout
saffron compound
transaction
user
BHST Transcript
BioHarvest Sciences Inc. (BHST) Q3 2025 Earnings Call Transcript
Positive11-13
The earnings call highlights strong revenue growth, improved gross margins, and a strategic focus on expanding VINIA products and CDMO services. The Q&A section reveals positive sentiment towards new product launches and partnerships, despite some uncertainty in management's timeline clarity. The company's strategic initiatives and financial metrics indicate a positive outlook, leading to a positive sentiment rating.
BioHarvest Sciences Inc. (BHST) Q2 2025 Earnings Call Transcript
Positive8-11
The earnings call summary and Q&A reveal strong revenue growth, improved margins, and promising product launches, notably the VINIA 2X Chews and hydration product. The partnership with Tate & Lyle and significant CDMO pipeline add optimism. Despite increased operating expenses and net loss, the company manages tariff impacts well and plans further margin improvements. Analysts show positive sentiment towards product and channel expansions, boosting the outlook. These factors suggest a positive stock price movement, especially given the company's strategic focus on high-growth areas and market expansion.
BioHarvest Sciences Inc. (BHST) Q1 2025 Earnings Call Transcript
Positive5-15
The earnings call indicates strong revenue growth, improved gross margins, and promising future revenue expectations. Despite some operational risks and unclear management responses, the company's expansion into new product categories and CDMO services, along with AI integration, suggests a positive outlook. The lack of a shareholder return plan is a slight downside. Overall, the positive financial performance and strategic initiatives outweigh the concerns, leading to a positive sentiment.
BioHarvest Sciences Inc. (BHST) Q4 2024 Earnings Conference Call Transcript
Positive3-31
The company shows significant revenue growth and improved gross profit, despite a net loss. Optimistic guidance, strong VINIA sales, and new product launches like espresso pods support positive sentiment. Management effectively addresses working capital needs through partnerships. However, concerns remain due to debt financing and unclear responses on CDMO pipeline and clinical trial timelines. Overall, the financial improvements and strategic developments outweigh these concerns, suggesting a positive stock price movement.
BHST Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
